| Disease | DETERIORATION OBSERVED WITH PLACEBO.
IN THE GROUP OF PATIENTS WITH VERY MILD TO MILD COGNITIVE IMPAIRMENT, WHILE IN MORE SEVERE DEMENTIA, THE MEAN EGB EFFECT SHOULD BE CONSIDERED MORE IN TERMS OF STABILIZATION OR SLOWING DOWN OF WORSENING, AS COMPARED TO THE GREATER
AND SOCIAL FUNCTIONING (P=0.001) REGARDLESS OF THE STAGE OF DEMENTIA, WHETHER MILD OR MODERATELY SEVERE. HOWEVER, THE RELATIVE CHANGES FROM BASELINE MEASURED AT ENDPOINT DEPENDED HEAVILY ON THE SEVERITY AT BASELINE. IMPROVEMENT WAS OBSERVED
(ADAS-COG) AND THE GERIATRIC EVALUATION BY RELATIVE'S RATING INSTRUMENT (GERRI). THE RESULTS OF THE RETROSPECTIVE ANALYSIS INDICATED THAT A TREATMENT EFFECT FAVORABLE TO EGB COULD BE OBSERVED WITH RESPECT TO COGNITIVE PERFORMANCE (P=0.02)
PARALLEL-GROUP, MULTICENTER STUDY WITH 120MG OF EGB, USING CUTOFF POINTS OF 23 AND 14 FOR THE MINI-MENTAL STATE EXAMINATION (MMSE) SCORE, OUTCOME MEASURES USED WERE THE COGNITIVE SUBSCALE OF THE ALZHEIMER'S DISEASE ASSESSMENT SCALE
TO EXPLORE THE TREATMENT EFFECT OF EGB 761 (EGB) IN ALZHEIMER'S DISEASE DEPENDING ON BASELINE SEVERITY. METHODS: WE APPLIED STRATIFICATION TO THE INTENTTO-TREAT DATA SET COLLECTED DURING A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,
A COMMERCIAL PRODUCT, EGB-761, WAS USED. |